Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+

Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.
Cancer Therapy Advisor

Pembrolizumab-Based Regimen Approved for Platinum-Resistant Ovarian Cancer

A companion diagnostic test was simultaneously approved to identify eligible patients whose tumors express PD-L1 with a combined positive score of 1 or higher.

Biocon banks on new launches, insulin capacity expansion to drive growth

Biocon aims for growth through new biosimilar launches and expanded insulin capacity, projecting significant revenue contributions from key products.
The Manila Times

VRC Medical Services Launches Dedicated Comparator Support Program for Biosimilar Clinical Trials

VRC Medical Services, a women-owned specialty pharmaceutical distribution company supporting clinical research, announced the launch of a dedicated comparator support program designed to help ...
Le Lézard

STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi

Global specialty, generic and consumer healthcare medicines company STADA and Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...